Mazor Robotics Ltd – (NASDAQ:MZOR) rose 2.1% during trading on Wednesday . The stock traded as high as $23.98 and last traded at $23.87, with a volume of 65,759 shares trading hands. The stock had previously closed at $23.38.

MZOR has been the subject of several research reports. Wells Fargo & Co. raised Mazor Robotics Ltd – from a “market perform” rating to an “outperform” rating in a research note on Thursday, May 19th. Zacks Investment Research raised Mazor Robotics Ltd – from a “sell” rating to a “hold” rating in a research note on Tuesday, June 14th. Barclays PLC lifted their target price on Mazor Robotics Ltd – from $16.00 to $23.00 and gave the company an “overweight” rating in a research note on Thursday, July 14th. Needham & Company LLC reissued a “hold” rating on shares of Mazor Robotics Ltd – in a research note on Tuesday, August 2nd. Finally, Standpoint Research initiated coverage on Mazor Robotics Ltd – in a research note on Friday, July 8th. They set a “buy” rating and a $30.00 price objective for the company. Three investment analysts have rated the stock with a hold rating and three have given a buy rating to the company. Mazor Robotics Ltd – has a consensus rating of “Buy” and a consensus target price of $25.00.

The company’s market capitalization is $506.23 million. The company has a 50 day moving average price of $21.56 and a 200 day moving average price of $14.93.

Mazor Robotics Ltd – (NASDAQ:MZOR) last released its earnings results on Tuesday, August 2nd. The company reported ($0.09) earnings per share for the quarter, topping the consensus estimate of ($0.11) by $0.02. The business had revenue of $8.30 million for the quarter, compared to the consensus estimate of $8.51 million. During the same quarter in the previous year, the company earned ($0.05) earnings per share. The firm’s revenue for the quarter was up 6.4% on a year-over-year basis. Equities analysts anticipate that Mazor Robotics Ltd – will post ($0.63) EPS for the current year.

Mazor Robotics Ltd is an Israel-based medical device company that develops and markets surgical guidance systems and complementary products. It develops computerized and imaging-based systems in the field of spine surgery. Its products include: Renaissance Surgical Guidance System, which enables surgeons to advance from freehand surgical procedures to guided procedures, as well as Food and Drug Administration (FDA)-cleared and European Conformity (CE)-marked Renaissance System, used in spine surgeries, whether open or minimally invasive, for a number of clinical indications.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.